RxDoctor Payments Data

Laura Martinez, MD

Urology · Sugar Land, TXNPI 1154615060

Payments from drug & device makers

$8,256in general payments, 2019–2025

Across 292 payments — averaging $28.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Boston Scientific$890
  • Valencia Technologies Corporation$719
  • AbbVie$716
  • Sumitomo Pharma America, Inc.$502
  • Endo Pharmaceuticals Inc.$439
  • plus $4K from 44 others

What the payments were for

  • Travel & lodging$6077%
  • Food & beverage$7,64993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,256 in reported general payments places this provider in the 70th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$174,661
Medicare patients
431
Services billed
2,710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron310$246,524
MyrbetriqMirabegron133$88,804
Estradiol242$16,664
EstringEstradiol19$10,154
Trospium Chloride ErTrospium Chloride33$5,912
Methenamine Hippurate45$4,209
ImvexxyEstradiol11$2,508
Tamsulosin Hcl105$1,843
Trospium Chloride28$1,789
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst117$1,680
YuvafemEstradiol14$1,399
Finasteride51$1,106
Cefpodoxime Proxetil19$764
Oxybutynin Chloride ErOxybutynin Chloride22$703
NitrofurantoinNitrofurantoin Macrocrystal16$690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$502$246,524310 claims
Astellas Pharma US IncMyrbetriq$69$88,804133 claims
PfizerEstring$21$10,15419 claims
Therapeuticsmd, Inc.Imvexxy$16$2,50811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 878 urology providers in Texas.

Other urology in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →